In vitro cytotoxicity assessment of biosynthesized nanoceria against MCF-7 breast cancer cell lines

Breast cancer poses a significant health concern due to its increasing prevalence and mortality rates. Hence, prompt action is needed to develop innovative therapeutic interventions, as conventional treatments exhibit severe adverse effects and have limited efficacy. This study aims to develop an innovative therapeutic intervention for breast cancer using biosynthesized nanoceria. Nanoceria has gained significant importance in the medicinal field due to its biocompatibility, dual capabilities as both antioxidant and prooxidant, and specific cytotoxicity towards cancer cells. Herein, nanoceria was biosynthesized using Echinochloa frumentaceae grain extract (EFNC) due to its eco-friendly and cost-efficient nature, and it was systematically investigated using standard characterization techniques. Furthermore, their anticancer efficacy against MCF-7 breast cancer cell lines was studied using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) cell viability assay, and the occurrence of apoptosis was determined using acridine orange/ethidium bromide (AO/EtBr) staining. Significantly, EFNC exhibited superior anticancer efficacy even at lower concentrations (10 µg/mL), and the IC₅₀ value was found at 47.32 µg/mL. In addition, the observed bright green and orange-red fluorescence, along with fragmented/condensed chromatin features in AO/EtBr staining clearly indicated that the EFNC caused cell death through the apoptotic route. One potential factor contributing to the observed anticancer effectiveness of EFNC could be its prooxidant properties within cancer cells. These properties ultimately enhanced oxidative stress, induced the accumulation of reactive oxygen species (ROS), and led to apoptosis. Hence, the in vitro analysis substantiated the significant anticancer efficacy of EFNC, suggesting its potential utility as a promising therapeutic agent in anticancer treatment. These findings pave the way for further exploration and development of EFNC as a valuable candidate for addressing cancer-related challenges.